Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Moderna Inc (NASDAQ: MRNA) was $33.85 for the day, down -0.94% from the previous closing price of $34.17. In other words, the price has decreased by -$0.94 from its previous closing price. On the day, 6.93 million shares were traded. MRNA stock price reached its highest trading level at $34.86 during the session, while it also had its lowest trading level at $33.51.
Ratios:
Our analysis of MRNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Neutral rating and assigned the stock a target price of $40.
On February 18, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $111 to $45.
Goldman Downgraded its Buy to Neutral on January 29, 2025, whereas the target price for the stock was revised from $99 to $51.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 03 ’25 when Bancel Stephane bought 160,314 shares for $31.22 per share. The transaction valued at 5,004,318 led to the insider holds 9,210,686 shares of the business.
SAGAN PAUL bought 31,620 shares of MRNA for $1,004,251 on Mar 03 ’25. The Director now owns 312,027 shares after completing the transaction at $31.76 per share. On Dec 09 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 529 shares for $44.68 each. As a result, the insider received 23,637 and left with 20,446 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 13210910720 and an Enterprise Value of 6781867520. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.04 while its Price-to-Book (P/B) ratio in mrq is 1.20. Its current Enterprise Value per Revenue stands at 2.096 whereas that against EBITDA is -1.806.
Stock Price History:
The Beta on a monthly basis for MRNA is 2.20, which has changed by -0.6939145 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $29.25. The 50-Day Moving Average of the stock is -3.09%, while the 200-Day Moving Average is calculated to be -48.53%.
Shares Statistics:
MRNA traded an average of 11.42M shares per day over the past three months and 7516640 shares per day over the past ten days. A total of 386.00M shares are outstanding, with a floating share count of 341.66M. Insiders hold about 11.44% of the company’s shares, while institutions hold 70.77% stake in the company. Shares short for MRNA as of 1741910400 were 46881859 with a Short Ratio of 3.95, compared to 1739491200 on 42296108. Therefore, it implies a Short% of Shares Outstanding of 46881859 and a Short% of Float of 16.84.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Moderna Inc (MRNA) is currently drawing attention from 10.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$3.08, with high estimates of -$2.87 and low estimates of -$3.57.
Analysts are recommending an EPS of between -$8.28 and -$11.27 for the fiscal current year, implying an average EPS of -$10.16. EPS for the following year is -$7.77, with 19.0 analysts recommending between -$2.06 and -$9.59.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 12 analysts. It ranges from a high estimate of $183M to a low estimate of $83M. As of the current estimate, Moderna Inc’s year-ago sales were $167MFor the next quarter, 12 analysts are estimating revenue of $114.37M. There is a high estimate of $172M for the next quarter, whereas the lowest estimate is $39M.
A total of 25 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $2.88B, while the lowest revenue estimate was $1.51B, resulting in an average revenue estimate of $2.18B. In the same quarter a year ago, actual revenue was $3.24BBased on 23 analysts’ estimates, the company’s revenue will be $2.67B in the next fiscal year. The high estimate is $5.38B and the low estimate is $1.87B.
